医学临床研究2024,Vol.41Issue(8) :1182-1184,1187.DOI:10.3969/j.issn.1671-7171.2024.08.018

双歧杆菌四联活菌片联合抗生素对重症肺炎患儿的肺部超声评分、肠道菌群及炎症因子水平的影响

Clinical Efficacy of Bifidobacterium Quadripartitum Active Tablets Combined with Antibiotics in Severe Pneumonia Children and their Impact on Gut Microbiota and Inflammatory Cytokine Levels

陈亚君 解俊奇 员亮亮
医学临床研究2024,Vol.41Issue(8) :1182-1184,1187.DOI:10.3969/j.issn.1671-7171.2024.08.018

双歧杆菌四联活菌片联合抗生素对重症肺炎患儿的肺部超声评分、肠道菌群及炎症因子水平的影响

Clinical Efficacy of Bifidobacterium Quadripartitum Active Tablets Combined with Antibiotics in Severe Pneumonia Children and their Impact on Gut Microbiota and Inflammatory Cytokine Levels

陈亚君 1解俊奇 1员亮亮1
扫码查看

作者信息

  • 1. 许昌医院,河南 许昌 461000
  • 折叠

摘要

[目的]探讨双歧杆菌四联活菌片联合抗生素对重症肺炎(SP)患儿的肺部超声评分(LUS)、肠道菌群及炎症因子水平的影响.[方法]选取2021年1月至2023年8月本院收治的102例SP患儿,依据随机数字表法分为对照组(常规对症治疗及抗生素治疗)和观察组(在对照组的基础上联合双歧杆菌四联活菌片),每组51例.比较两组临床疗效及治疗前后肺功能指标[第1秒用力呼气容积(FEV1)、肺活量(VC)、LUS]、肠道菌群(大肠杆菌、双歧杆菌、肠球菌、乳酸杆菌)、炎症因子[白细胞介素(IL-10)、C反应蛋白(CRP)、可溶性细胞间黏附分子1(sICAM-1)、肿瘤坏死因子(TNF-α)]水平.[结果]观察组总有效率高于对照组,差异有统计学意义(P<0.05).治疗后,两组FEV1及VC高于治疗前,两组LUS低于治疗前,且观察组与对照组比较,差异有统计学意义(P<0.05);两组双歧杆菌、乳酸杆菌水平高于治疗前,肠球菌及大肠杆菌低于治疗前,且观察组与对照组比较,差异有统计学意义(P<0.05);两组血清IL-10水平高于治疗前,CRP、sICAM-1、TNF-α水平低于治疗前,且观察组与对照组比较,差异有统计学意义(P<0.05).[结论]双歧杆菌四联活菌片联合抗生素治疗SP患儿临床疗效较好,可抑制炎症反应,改善患儿肺功能.

Abstract

[Objective]To investigate the clinical efficacy of Bifidobacterium quadruple active tablets com-bined with antibiotics in severe pneumonia(SP)children on gut microbiota,pulmonary ultrasound score(LUS)and inflammatory cytokine levels.[Methods]A total of 102 children with SP admitted to our hospital from Jan-uary 2021 to August 2023 were selected and randomly divided into the control group(conventional symptomat-ic treatment and antibiotic treatment)and the observation group(combined with Bifidobacterium quadruple vi-able tablets on the basis of the control group)using a random number table method,with 51 cases in each group.Two groups were compared in terms of clinical efficacy,pre-and post-treatment lung function indicators[forced expiratory volume in one second(FEV1),vital capacity(VC),LUS],gut microbiota[Escherichia co-li,Bifidobacterium,Enterococcus,Lactobacillus],inflammatory factors[interleukin(IL-10),C-reactive pro-tein(CRP),soluble intercellular adhesion molecule-1(sICAM-1),tumor necrosis factor alpha(TNF-α)]lev-els.[Results]The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,FEV1,and VC in both groups were higher than before treatment,LUS was lower than before treatment,the difference was statistical significance in two groups(P<0.05);The levels of Bifidobacterium and Lactobacillus in both groups were higher than be-fore treatment,while the levels of Enterococcus and Escherichia coli were lower than before treatment.The difference between the observation group and the control group was statistically significant(P<0.05);The levels of IL-10 in both groups were higher than before treatment,while the levels of CRP,sICAM-1,and TNF-α were lower than before treatment.The difference between the observation group and the control group was statistically significant(P<0.05).[Conclusion]The combination of Bifidobacterium quadruple active tablets and antibiotics has good clinical efficacy in treating SP children,inhibiting inflammatory reactions,and improving lung function in children.

关键词

肺炎/药物疗法/乳杆菌属/治疗应用/抗菌药/治疗应用/肠/微生物学/儿童

Key words

Pneumonia/DT/Lactobacillus/TU/Anti-Bacterial Agents/TU/Intestines/MI/Child

引用本文复制引用

出版年

2024
医学临床研究
湖南省医学会

医学临床研究

影响因子:0.595
ISSN:1671-7171
段落导航相关论文